Blueprint Medicines Overview
Blueprint Medicines Target Price
Analysts' 12-month price predictions for BPMC.
Share Price
$99.41
Average Target Price
$150.00
50.9% upside
50.9% upside1 analysts in the last 4 months
High: $150 | Low: $150
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-03-07 | Scotiabank | $150 | 50.9% upside |  |
| 2024-10-31 | NeedhamAmi Fadia | $135 | 35.8% upside | |
| 2024-10-24 | UBSDavid Dai | $88 |  11.5% downside | |
| 2024-09-19 | Stifel NicolausBradley Canino | $155 | 55.9% upside | |
| 2024-08-01 | OppenheimerMatthew Biegler | $130 | 30.8% upside | |
| 2024-07-29 | BarclaysPeter Lawson | $105 | 5.6% upside | |
| 2024-07-08 | OppenheimerMatthew Biegler | $125 | 25.7% upside | |
| 2024-05-06 | Leerink PartnersAndrew Berens | $97 | 2.4% downside | |
| 2024-05-03 | Raymond JamesChristopher Raymond | $104 | 4.6% upside | |
| 2024-05-03 | H.C. WainwrightAndrew Fein | $135 | 35.8% upside | |
| 2022-12-14 | Needham | $60 | 39.6% downside | |
| 2022-11-02 | H.C. WainwrightAndrew Fein | $70 | 29.6% downside | |
| 2022-09-06 | OppenheimerMatthew Biegler | $90 | 9.5% downside | |
| 2022-08-17 | Wells FargoDerek Archila | $41 | 58.8% downside | |
| 2022-05-18 | Piper SandlerChristopher Raymond | $65 | 34.6% downside | |
| 2022-02-01 | Morgan StanleyMichael Ulz | $92 | 7.4% downside | |
| 2022-01-03 | GuggenheimMichael Schmidt | $122 | 22.7% upside | |
| 2021-11-09 | Raymond JamesDane Leone | $133 | 33.8% upside | |
| 2021-07-29 | Goldman SachsSalveen Richter | $147 | 47.9% upside | |
| 2021-06-17 | Canaccord GenuityArlinda Lee | $120 | 20.7% upside | |